MTOR and medical procedure: In 1999, sirolimus became the first mTOR inhibitor approved for use as an immunosuppressant in kidney transplant recipients by the U.S. Food and Drug Administration, and it remains the most commonly used mTOR inhibitor in kidney recipients in the United States 8.